/Vertex%20Pharmaceuticals%2C%20Inc_%20HQ%20in%20Boston-by%20Tada%20Images%20via%20Shuttershock.jpg)
Boston, Massachusetts-based Vertex Pharmaceuticals Incorporated (VRTX) develops and commercializes therapies for treating cystic fibrosis (CF). Valued at $119.6 billion by market cap, the company invests in scientific innovation to create transformative medicines for people with serious diseases.
Shares of the biotechnology company have outperformed the broader market considerably over the past year. VRTX has gained 32.7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 31.8%. However, in 2024, VRTX’s stock rose 14.2%, compared to the SPX’s 25.8% rise on a YTD basis.